San Francisco, California
Cancer clinical trials in San Francisco, CA
214 cancer studies are recruiting participants at sites in San Francisco as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
San Francisco at a glance
- 214 studies are recruiting at a site in San Francisco.
- By phase: Early Phase 1 (4), Phase 1 (33), Phase 1/2 (28), Phase 2 (46), Phase 2/3 (5), Phase 3 (58), No phase (14), Observational (26). Studies of devices and behavioral approaches have no phase.
- By sponsor: university, hospital or other (102), industry (98), government (14).
- By research area: Breast Cancer (58), Prostate Cancer (45), Lung Cancer (41), Lymphoma (40), Melanoma (15), Pancreatic Cancer (15).
- Most recent update to one of these records: November 16, 2026.
Breast cancer studies recruiting in San Francisco
Basic details from each study's public record (the 30 most recently updated of 214). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- California Pacific Medical Center-Pacific Campus
- Registry record
- NCT06058377 · updated
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Stemline Therapeutics, Inc.
- Study site
- UCSF Helen Diller Family Comprehensive Cancer Center
- Registry record
- NCT06638307 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0016)
- Registry record
- NCT06841354 · updated
Mirai-MRI: Validation of AI Models for Breast Cancer Risk
- No phase
- Ages 40 to 89
- Female participants
- Sponsor
- University of California, San Francisco
- Study site
- University of California, San Francisco
- Registry record
- NCT07121972 · updated
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- University of California, San Francisco
- Study site
- University of California, San Francisco
- Registry record
- NCT05964504 · updated
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- California Pacific Medical Center-Pacific Campus
- Registry record
- NCT07391774 · updated
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- ORIC Pharmaceuticals
- Study site
- University of California, San Francisco
- Registry record
- NCT05315700 · updated
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Kaiser Permanente - San Francisco ( Site 0080)
- Registry record
- NCT06393374 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in San Francisco, CA on ClinicalTrials.gov.
Lung cancer studies recruiting in San Francisco
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- California Pacific Medical Center-Pacific Campus · Kaiser Permanente-San Francisco
- Registry record
- NCT04267848 · updated
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UCSF Medical Center-Mission Bay
- Registry record
- NCT04665739 · updated
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Kaiser Permanente-San Francisco
- Registry record
- NCT06498635 · updated
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Bayer
- Study site
- UCSF Helen Diller Medical Center at Parnassus Heights - Neurology
- Registry record
- NCT06914128 · updated
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- SystImmune Inc.
- Study site
- UCSF- San Francisco (Helen Diller Family Comprehensive Cancer Center)
- Registry record
- NCT07080242 · updated
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- San Francisco Oncology Associates ( Site 0066)
- Registry record
- NCT06312137 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- UCSF Medical Center at Mission Bay ( Site 0178)
- Registry record
- NCT06623422 · updated
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- UCSF Health - UCSF Helen Diller Family Comprehensive Cancer Center
- Registry record
- NCT07566052 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in San Francisco, CA on ClinicalTrials.gov.
Prostate cancer studies recruiting in San Francisco
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- Phase 1
- Ages 18 and older
- Male participants
- Sponsor
- Amgen
- Study site
- University of California San Francisco
- Registry record
- NCT04221542 · updated
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
- No phase
- Ages 18 and older
- Male participants
- Sponsor
- Axonics, Inc.
- Study site
- University of California San Francisco
- Registry record
- NCT06511141 · updated
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
- Phase 1
- Ages 18 and older
- Male participants
- Sponsor
- University of California, San Francisco
- Study site
- University of California, San Francisco
- Registry record
- NCT07145177 · updated
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
- Phase 2
- Ages 18 and older
- Male participants
- Sponsor
- Hoffmann-La Roche
- Registry record
- NCT07287150 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in San Francisco, CA on ClinicalTrials.gov.
Melanoma studies recruiting in San Francisco
A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
- Phase 1
- Ages 18 and older
- Female participants
- Sponsor
- Outpace Bio, Inc.
- Study site
- UCSF - Helen Diller Family Comprehensive Cancer Center
- Registry record
- NCT07664735 · updated
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- University of California, San Francisco
- Study site
- University of California, San Francisco
- Registry record
- NCT07148245 · updated
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- University of California San Francisco (UCSF)
- Registry record
- NCT06246916 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in San Francisco, CA on ClinicalTrials.gov.
Lymphoma studies recruiting in San Francisco
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Zuckerberg San Francisco General Hospital
- Registry record
- NCT06806033 · updated
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Nurix Therapeutics, Inc.
- Study site
- University of California, San Francisco
- Registry record
- NCT07221500 · updated
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Pacific Hematology Oncology Associates ( Site 0131)
- Registry record
- NCT06717347 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UCSF Medical Center-Mission Bay
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Kaiser Permanente-San Francisco
- Registry record
- NCT05675410 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in San Francisco, CA on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in San Francisco
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Incyte Corporation
- Study site
- Investigative Site US034
- Registry record
- NCT07522073 · updated
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- California Pacific Medical Center-Pacific Campus
- Registry record
- NCT04858334 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in San Francisco, CA on ClinicalTrials.gov.
Ask about studies near San Francisco
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in California
All California locations
984 studies recruiting across 150 cities.
Los Angeles
384 studies recruiting.
Duarte
250 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections